Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase 2 Trial of Lenalidomide/ Dexamethasone/ Elotuzumab +/- Cyclophosphamide Followed by Lenalidomide/ Dexamethasone/Elotuzumab Maintenance as Second-Line Therapy for Patients With Relapsed AL Amyloidosis

Trial Profile

A Randomized Phase 2 Trial of Lenalidomide/ Dexamethasone/ Elotuzumab +/- Cyclophosphamide Followed by Lenalidomide/ Dexamethasone/Elotuzumab Maintenance as Second-Line Therapy for Patients With Relapsed AL Amyloidosis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Feb 2019

At a glance

  • Drugs Cyclophosphamide (Primary) ; Dexamethasone (Primary) ; Elotuzumab (Primary) ; Lenalidomide (Primary)
  • Indications Amyloid light-chain amyloidosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Feb 2019 Planned End Date changed from 31 Dec 2020 to 31 Dec 2022.
    • 06 Feb 2019 Planned primary completion date changed from 30 Sep 2019 to 30 Sep 2020.
    • 07 Sep 2017 Planned End Date changed from 31 Dec 2019 to 31 Dec 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top